{
  "38P.F": {
    "city": "Tampere",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "Pihlajalinna Oyj",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PIHLAJALINNA OY",
    "state": null,
    "summary": "Pihlajalinna Oyj provides social and healthcare services for private persons, companies, insurance companies, municipalities, and hospital districts in Finland. It offers general practitioner and medical specialist services, occupational healthcare, social and healthcare outsourcing, fitness center services, responsible doctor, and remote consultation services, as well as residential and staffing services. Its specialized care and services, include orthopedics and surgery, internal medicine, neurology, cardiology, geriatrics, surgery, plastic surgery, psychiatry, internal medicine cardiology, lung diseases, dialysis, urology, ENT, gynecology, radiology, and general medicine, as well as emergency and on-call, dental care, substance abuse clinic, and family service center services. Pihlajalinna Oyj was founded in 2001 and is headquartered in Tampere, Finland.",
    "website": "http://www.pihlajalinna.fi",
    "zipcode": "33200"
  },
  "4TS.F": {
    "city": "Helsinki",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "Terveystalo Oyj",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "TERVEYSTALO OYJ",
    "state": null,
    "summary": "Terveystalo Oyj provides occupational healthcare services in Finland. The company offers general practice and specialist medical care, diagnostic, outpatient surgery, dental, and other adjacent services; and laboratory, imaging, wellbeing, day surgery, healthcare outsourcing, healthcare staffing, and primary and specialty care services. It also provides a suite of digital healthcare services; and clinical research services. The company serves private individuals, companies and communities, insurance companies, and public sector customers. It operates 309 clinics, which include 17 hospital units and 43 dental clinics; and 53 rela massage therapy units. The company was founded in 2001 and is based in Helsinki, Finland.",
    "website": "http://www.terveystalo.com",
    "zipcode": "00100"
  },
  "4YL.F": {
    "city": "Helsinki",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Nanoform Finland Oyj",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "NANOFORM FINLAND OYJ",
    "state": null,
    "summary": "Nanoform Finland Oy provides nanotechnology and drug particle engineering services for the pharmaceutical and biotechnology industries in Finland and internationally. The company provides nanoparticle production services using its proprietary controlled expansion of supercritical solutions technology that enables clients in the creation of active pharmaceutical ingredients nanoparticles directly from solution. Its technology and services help in increasing the bioavailability of drug molecules and developing new drugs. The company was founded in 2015 and is headquartered in Helsinki, Finland.",
    "website": "http://www.nanoform.com",
    "zipcode": "00790"
  },
  "5NXA.F": {
    "city": "Helsinki",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Nexstim Plc",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "NEXSTIM OYJ",
    "state": null,
    "summary": "Nexstim Plc, a neuromodulation company, engages in the development and marketing of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company's proprietary SmartFocus technology with 3D navigation is the navigated transcranial magnetic stimulation (TMS) approach that is used for therapeutic and diagnostic applications. It offers NBT system, a navigated brain therapy system for the treatment of major depression order or chronic neuropathic pain; and NBS system, a navigated brain stimulation system for pre-surgical mapping of the speech and motor cortices of the brain. The company primarily sells its NBS systems to universities and teaching hospitals. Nexstim Plc was founded in 2000 and is headquartered in Helsinki, Finland.",
    "website": "http://www.nexstim.com",
    "zipcode": "00510"
  },
  "7XE.F": {
    "city": "Helsinki",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "Nightingale Health Oyj",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NIGHTINGALE HEALTH  EO 1",
    "state": null,
    "summary": "Nightingale Health Ltd. offers a health data platform that detects disease risks. The company's platform allows individuals to access disease risk information and take actions to prevent diseases. It serves healthcare service providers and direct consumers. The company was founded in 2002 and is based in Helsinki, Finland.",
    "website": "http://nightingalehealth.com",
    "zipcode": "00300"
  },
  "BIOBV.HE": {
    "city": "Helsinki",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "HEL",
    "industry": "Biotechnology",
    "long_name": "Biohit Oyj",
    "market": "fi_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Biohit Oyj B",
    "state": null,
    "summary": "Biohit Oyj, a biotechnology company, produces diagnostic tests and analysis systems for use in research institutions and healthcare industries worldwide. The company's diagnostic tests product range includes the GastroPanel test for diagnosing diseases of the stomach and associated risks; Biohit Active B12, a test for measuring the levels of active vitamin B12; Biohit Total, an indicator of vitamin D status; Biohit Calprotectin, a test for measuring human calprotectin; Helicobacter Pylori Quick Test and Helicobacter Pylori UFT300 Quick Test, a test methods to detect H. pylori infection from a biopsy sample during gastroscopy; ColonView Quick Test, a test for detection of fecal occult blood; Lactose Intolerance Quick Test; Celiac Disease Quick Test; and The GA-map Dysbiosis test, a gut microbiota DNA analysis tool. It also provides monoclonal antibodies for use in cellular pathology, neurobiology, oncology, and human gastric biomarkers research. In addition, the company offers acetaldehyde binding products, such as Acetium capsules that are intended for persons with a low-acid or anacidic stomach; and Acetium lozenges, which removes acetaldehyde in smoker's saliva. Further, it provides microplate readers and strip washers, quick test readers, and ThunderBolt, an automated immunoassay analyzer; and products that bind carcinogenic acetaldehyde into harmless compounds, monoclonal antibodies, and service laboratory services. The company was founded in 1988 and is headquartered in Helsinki, Finland.",
    "website": "http://www.biohithealthcare.com",
    "zipcode": "00880"
  },
  "BONEH.HE": {
    "city": "Oulu",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "HEL",
    "industry": "Medical Devices",
    "long_name": "BBS-Bioactive Bone Substitutes Oyj",
    "market": "fi_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "BBS-Bioactive Bone Substitutes",
    "state": null,
    "summary": "BBS-Bioactive Bone Substitutes Oyj, a biomedical technology company, develops, designs, manufactures, and sells bioactive medical devices and implants for orthopedic surgery in Finland. It offers ARTEBON, an orthobiological product based on tricalcium phosphate and natural spectrum of bone proteins. The company was founded in 2003 and is headquartered in Oulu, Finland.",
    "website": "http://www.bbs-artebone.fi",
    "zipcode": "90220"
  },
  "BONES.ST": {
    "city": "Oulu",
    "country": "Finland",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "BBS-Bioactive Bone Substitutes Oyj",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "BBS-Bioactive Bone Substitutes",
    "state": null,
    "summary": "BBS-Bioactive Bone Substitutes Oyj, a biomedical technology company, develops, designs, manufactures, and sells bioactive medical devices and implants for orthopedic surgery in Finland. It offers ARTEBON, an orthobiological product based on tricalcium phosphate and natural spectrum of bone proteins. The company was founded in 2003 and is headquartered in Oulu, Finland.",
    "website": "http://www.bbs-artebone.fi",
    "zipcode": "90220"
  },
  "FARN.L": {
    "city": "Turku",
    "country": "Finland",
    "currency": "GBp",
    "exchange": "LSE",
    "industry": "Biotechnology",
    "long_name": "Faron Pharmaceuticals Oy",
    "market": "gb_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "FARON PHARMACEUTICALS OY ORD NP",
    "state": null,
    "summary": "Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute trauma, cancer growth and spread, and inflammatory diseases. The company's lead product candidates are Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS); and Clevegen, an immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.",
    "website": "http://www.faron.com",
    "zipcode": "20520"
  },
  "FARON.HE": {
    "city": "Turku",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "HEL",
    "industry": "Biotechnology",
    "long_name": "Faron Pharmaceuticals Oy",
    "market": "fi_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Faron Pharmaceuticals Oy",
    "state": null,
    "summary": "Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute trauma, cancer growth and spread, and inflammatory diseases. The company's lead product candidates are Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS); and Clevegen, an immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.",
    "website": "http://www.faron.com",
    "zipcode": "20520"
  },
  "HEALTH.HE": {
    "city": "Helsinki",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "HEL",
    "industry": "Health Information Services",
    "long_name": "Nightingale Health Oyj",
    "market": "fi_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Nightingale Health Oyj B",
    "state": null,
    "summary": "Nightingale Health Ltd. offers a health data platform that detects disease risks. The company's platform allows individuals to access disease risk information and take actions to prevent diseases. It serves healthcare service providers and direct consumers. The company was founded in 2002 and is based in Helsinki, Finland.",
    "website": "http://nightingalehealth.com",
    "zipcode": "00300"
  },
  "HRNTS.ST": {
    "city": "Espoo",
    "country": "Finland",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Herantis Pharma Oyj",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Herantis Pharma Oyj",
    "state": null,
    "summary": "Herantis Pharma Oyj, a drug development company, focuses on developing regenerative therapeutics. Its products in pipeline includes Cerebral Dopamine Neurotrophic Factor (CDNF), which is in Phase 1-2 clinical trial for the treatment of Parkinson's disease; xCDNF, an engineered derivative to treat neurodegenerative diseases; and Lymfactin, which is in Phase II clinical trial for the treatment of breast cancer related lymphedema. The company was founded in 2008 and is based in Espoo, Finland.",
    "website": "http://www.herantis.com",
    "zipcode": "02600"
  },
  "HRPMF": {
    "city": "Espoo",
    "country": "Finland",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Herantis Pharma Oyj",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "HERANTIS PHARMA OYJ",
    "state": null,
    "summary": "Herantis Pharma Oyj, a drug development company, focuses on developing regenerative therapeutics. Its products in pipeline includes Cerebral Dopamine Neurotrophic Factor (CDNF), which is in Phase 1-2 clinical trial for the treatment of Parkinson's disease; xCDNF, an engineered derivative to treat neurodegenerative diseases; and Lymfactin, which is in Phase II clinical trial for the treatment of breast cancer related lymphedema. The company was founded in 2008 and is based in Espoo, Finland.",
    "website": "http://www.herantis.com",
    "zipcode": "02600"
  },
  "HRTIS.HE": {
    "city": "Espoo",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "HEL",
    "industry": "Biotechnology",
    "long_name": "Herantis Pharma Oyj",
    "market": "fi_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Herantis Pharma Oyj",
    "state": null,
    "summary": "Herantis Pharma Oyj, a drug development company, focuses on developing regenerative therapeutics. Its products in pipeline includes Cerebral Dopamine Neurotrophic Factor (CDNF), which is in Phase 1-2 clinical trial for the treatment of Parkinson's disease; xCDNF, an engineered derivative to treat neurodegenerative diseases; and Lymfactin, which is in Phase II clinical trial for the treatment of breast cancer related lymphedema. The company was founded in 2008 and is based in Espoo, Finland.",
    "website": "http://www.herantis.com",
    "zipcode": "02600"
  },
  "NANOFH.HE": {
    "city": "Helsinki",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "HEL",
    "industry": "Biotechnology",
    "long_name": "Nanoform Finland Oyj",
    "market": "fi_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Nanoform Finland Oyj",
    "state": null,
    "summary": "Nanoform Finland Oy provides nanotechnology and drug particle engineering services for the pharmaceutical and biotechnology industries in Finland and internationally. The company provides nanoparticle production services using its proprietary controlled expansion of supercritical solutions technology that enables clients in the creation of active pharmaceutical ingredients nanoparticles directly from solution. Its technology and services help in increasing the bioavailability of drug molecules and developing new drugs. The company was founded in 2015 and is headquartered in Helsinki, Finland.",
    "website": "http://www.nanoform.com",
    "zipcode": "00790"
  },
  "NANOFS.ST": {
    "city": "Helsinki",
    "country": "Finland",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Nanoform Finland Oyj",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Nanoform Finland Oyj",
    "state": null,
    "summary": "Nanoform Finland Oy provides nanotechnology and drug particle engineering services for the pharmaceutical and biotechnology industries in Finland and internationally. The company provides nanoparticle production services using its proprietary controlled expansion of supercritical solutions technology that enables clients in the creation of active pharmaceutical ingredients nanoparticles directly from solution. Its technology and services help in increasing the bioavailability of drug molecules and developing new drugs. The company was founded in 2015 and is headquartered in Helsinki, Finland.",
    "website": "http://www.nanoform.com",
    "zipcode": "00790"
  },
  "NXTMH.HE": {
    "city": "Helsinki",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "HEL",
    "industry": "Medical Devices",
    "long_name": "Nexstim Plc",
    "market": "fi_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Nexstim Oyj",
    "state": null,
    "summary": "Nexstim Plc, a neuromodulation company, engages in the development and marketing of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company's proprietary SmartFocus technology with 3D navigation is the navigated transcranial magnetic stimulation (TMS) approach that is used for therapeutic and diagnostic applications. It offers NBT system, a navigated brain therapy system for the treatment of major depression order or chronic neuropathic pain; and NBS system, a navigated brain stimulation system for pre-surgical mapping of the speech and motor cortices of the brain. The company primarily sells its NBS systems to universities and teaching hospitals. Nexstim Plc was founded in 2000 and is headquartered in Helsinki, Finland.",
    "website": "http://www.nexstim.com",
    "zipcode": "00510"
  },
  "NXTMS.ST": {
    "city": "Helsinki",
    "country": "Finland",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Nexstim Plc",
    "market": "se_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Nexstim Oyj",
    "state": null,
    "summary": "Nexstim Plc, a neuromodulation company, engages in the development and marketing of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company's proprietary SmartFocus technology with 3D navigation is the navigated transcranial magnetic stimulation (TMS) approach that is used for therapeutic and diagnostic applications. It offers NBT system, a navigated brain therapy system for the treatment of major depression order or chronic neuropathic pain; and NBS system, a navigated brain stimulation system for pre-surgical mapping of the speech and motor cortices of the brain. The company primarily sells its NBS systems to universities and teaching hospitals. Nexstim Plc was founded in 2000 and is headquartered in Helsinki, Finland.",
    "website": "http://www.nexstim.com",
    "zipcode": "00510"
  },
  "O5O.F": {
    "city": "Espoo",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Oriola Oyj",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ORIOLA OYJ B",
    "state": null,
    "summary": "Oriola Oyj provides healthcare and wellbeing products in Sweden, Finland, and internationally.The company offers various range of OTC and traded good, vitamins, dietary supplements, pharmaceutical cosmetics, skincare products, tests, sports drinks, and wound care products. It also provides logistics, advisory, sales and marketing, and expert services for pharmaceutical companies, pharmacies, hospital pharmacies, veterinaries, as well as the grocery trade shops. In addition, the company offers pharmaceutical staffing and dose dispensing services for public and private healthcare operators, pharmacies, groceries, veterinarians, and retailers. As of December 31, 2020, it operated 325 pharmacies in Sweden, as well as operates online pharmacies. The company was formerly known as Oriola-KD Oyj and changed its name to Oriola Oyj in April 2017. Oriola Oyj is headquartered in Espoo, Finland.",
    "website": "http://www.oriola.com",
    "zipcode": "02200"
  },
  "OFK.F": {
    "city": "Espoo",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Orion Oyj",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ORION CORP. B",
    "state": null,
    "summary": "Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company has a collaboration with Nanoform to apply Nanoform's CESS technology to new chemical entities. It serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) line of inhalers for asthma and COPD to Propeller's digital medicine platform. Orion Oyj is headquartered in Espoo, Finland.",
    "website": "http://www.orion.fi",
    "zipcode": "02200"
  },
  "OKDAV.HE": {
    "city": "Espoo",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "HEL",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Oriola Oyj",
    "market": "fi_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Oriola Corporation A",
    "state": null,
    "summary": "Oriola Oyj provides healthcare and wellbeing products in Sweden, Finland, and internationally.The company offers various range of OTC and traded good, vitamins, dietary supplements, pharmaceutical cosmetics, skincare products, tests, sports drinks, and wound care products. It also provides logistics, advisory, sales and marketing, and expert services for pharmaceutical companies, pharmacies, hospital pharmacies, veterinaries, as well as the grocery trade shops. In addition, the company offers pharmaceutical staffing and dose dispensing services for public and private healthcare operators, pharmacies, groceries, veterinarians, and retailers. As of December 31, 2020, it operated 325 pharmacies in Sweden, as well as operates online pharmacies. The company was formerly known as Oriola-KD Oyj and changed its name to Oriola Oyj in April 2017. Oriola Oyj is headquartered in Espoo, Finland.",
    "website": "http://www.oriola.com",
    "zipcode": "02200"
  },
  "OKDBV.HE": {
    "city": "Espoo",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "HEL",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Oriola Oyj",
    "market": "fi_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Oriola Corporation B",
    "state": null,
    "summary": "Oriola Oyj provides healthcare and wellbeing products in Sweden, Finland, and internationally.The company offers various range of OTC and traded good, vitamins, dietary supplements, pharmaceutical cosmetics, skincare products, tests, sports drinks, and wound care products. It also provides logistics, advisory, sales and marketing, and expert services for pharmaceutical companies, pharmacies, hospital pharmacies, veterinaries, as well as the grocery trade shops. In addition, the company offers pharmaceutical staffing and dose dispensing services for public and private healthcare operators, pharmacies, groceries, veterinarians, and retailers. As of December 31, 2020, it operated 325 pharmacies in Sweden, as well as operates online pharmacies. The company was formerly known as Oriola-KD Oyj and changed its name to Oriola Oyj in April 2017. Oriola Oyj is headquartered in Espoo, Finland.",
    "website": "http://www.oriola.com",
    "zipcode": "02200"
  },
  "OPTOMED.HE": {
    "city": "Oulu",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "HEL",
    "industry": "Medical Devices",
    "long_name": "Optomed Oyj",
    "market": "fi_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Optomed Plc",
    "state": null,
    "summary": "Optomed Oyj, a medical technology company, provides handheld fundus cameras and eye-screening devices in Finland, China, and internationally. The company operates through two segments, Devices and Software segments. It offers handheld fundus camera products, which are used in ophthalmology, pediatric care, endocrinology, neurology, and primary care. Its product portfolio consists of Optomed Smartscope Pro, Optomed Aurora, and Optomed Aava, as well as OEM cameras, including Pictor Plus, Pictor Prestige, Visuscout 100, Fundus Module 300, and Signal; and desktops cameras, such as Optomed Polaris tabletop fundus cameras and Optomed Halo portable retinal cameras. The company also provides Optomed Avenue, a Software-as-a-Service (SaaS) platform that offers access to artificial intelligence services, screening process management tools, and remote image analyses; Avenue Eye Screen, a workflow management system for screening and monitoring of eye diseases, such as diabetic retinopathy; Avenue Telemedicine, a remote analysis solution for faster access to medical consultation; Avenue Viewer, a patient data management solution for viewing, reporting, and archiving fundus images; and Avenue Sync, a software solution. In addition, it offers process management software for various cancer screenings; radiology information system, a software system for healthcare imaging units for managing medical images and associated data; and solution for digital pathology. Further, the company provides professional IT consulting services for government institutions. It sells its products and solutions through OEMs, distributors, and direct sales. The company's customers include hospitals, eye clinics, and optician chains and stores. The company was founded in 2004 and is headquartered in Oulu, Finland.",
    "website": "http://www.optomed.com",
    "zipcode": "90230"
  },
  "ORINF": {
    "city": "Espoo",
    "country": "Finland",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Orion Oyj",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ORION CORPORATION",
    "state": null,
    "summary": "Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company has a collaboration with Nanoform to apply Nanoform's CESS technology to new chemical entities. It serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) line of inhalers for asthma and COPD to Propeller's digital medicine platform. Orion Oyj is headquartered in Espoo, Finland.",
    "website": "http://www.orion.fi",
    "zipcode": "02200"
  },
  "ORNAV.HE": {
    "city": "Espoo",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "HEL",
    "industry": "Drug Manufacturers - General",
    "long_name": "Orion Oyj",
    "market": "fi_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Orion Corporation A",
    "state": null,
    "summary": "Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company has a collaboration with Nanoform to apply Nanoform's CESS technology to new chemical entities. It serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) line of inhalers for asthma and COPD to Propeller's digital medicine platform. Orion Oyj is headquartered in Espoo, Finland.",
    "website": "http://www.orion.fi",
    "zipcode": "02200"
  },
  "ORNBV.HE": {
    "city": "Espoo",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "HEL",
    "industry": "Drug Manufacturers - General",
    "long_name": "Orion Oyj",
    "market": "fi_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Orion Corporation B",
    "state": null,
    "summary": "Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company has a collaboration with Nanoform to apply Nanoform's CESS technology to new chemical entities. It serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) line of inhalers for asthma and COPD to Propeller's digital medicine platform. Orion Oyj is headquartered in Espoo, Finland.",
    "website": "http://www.orion.fi",
    "zipcode": "02200"
  },
  "PIHLIS.HE": {
    "city": "Tampere",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "HEL",
    "industry": "Medical Care Facilities",
    "long_name": "Pihlajalinna Oyj",
    "market": "fi_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Pihlajalinna Oyj",
    "state": null,
    "summary": "Pihlajalinna Oyj provides social and healthcare services for private persons, companies, insurance companies, municipalities, and hospital districts in Finland. It offers general practitioner and medical specialist services, occupational healthcare, social and healthcare outsourcing, fitness center services, responsible doctor, and remote consultation services, as well as residential and staffing services. Its specialized care and services, include orthopedics and surgery, internal medicine, neurology, cardiology, geriatrics, surgery, plastic surgery, psychiatry, internal medicine cardiology, lung diseases, dialysis, urology, ENT, gynecology, radiology, and general medicine, as well as emergency and on-call, dental care, substance abuse clinic, and family service center services. Pihlajalinna Oyj was founded in 2001 and is headquartered in Tampere, Finland.",
    "website": "http://www.pihlajalinna.fi",
    "zipcode": "33200"
  },
  "R0V.MU": {
    "city": "Vantaa",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "MUN",
    "industry": "Medical Devices",
    "long_name": "Revenio Group Oyj",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "REVENIO GROUP CORP. EO 15",
    "state": null,
    "summary": "Revenio Group Oyj, a health technology company, designs, manufactures, and sells medical instruments for the early detection of glaucoma, diabetic retinopathy, and macular degeneration in Finland, Italy, rest of Europe, the United States, and internationally. The company offers ic100 and ic200 tonometers; Icare HOME, a device for self-measurement of eye pressure; Icare TONOVET Plus tonometers for animals; fundus imaging devices comprising EIDON, DRS, and DRSplus; MAIA, a microperimeter to measure the effectiveness of drugs for retinal disease treatment; COMPASS, which provides fundus perimetry with true-color confocal retinal images; and Ventica, to examine the variability in tidal breathing in children. It is also developing Cutica, a hyperspectral camera for dermatologists to detect skin cancers. Revenio Group Oyj is based in Vantaa, Finland.",
    "website": "http://www.reveniogroup.fi",
    "zipcode": "01510"
  },
  "REG1V.HE": {
    "city": "Vantaa",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "HEL",
    "industry": "Medical Devices",
    "long_name": "Revenio Group Oyj",
    "market": "fi_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Revenio Group Corporation",
    "state": null,
    "summary": "Revenio Group Oyj, a health technology company, designs, manufactures, and sells medical instruments for the early detection of glaucoma, diabetic retinopathy, and macular degeneration in Finland, Italy, rest of Europe, the United States, and internationally. The company offers ic100 and ic200 tonometers; Icare HOME, a device for self-measurement of eye pressure; Icare TONOVET Plus tonometers for animals; fundus imaging devices comprising EIDON, DRS, and DRSplus; MAIA, a microperimeter to measure the effectiveness of drugs for retinal disease treatment; COMPASS, which provides fundus perimetry with true-color confocal retinal images; and Ventica, to examine the variability in tidal breathing in children. It is also developing Cutica, a hyperspectral camera for dermatologists to detect skin cancers. Revenio Group Oyj is based in Vantaa, Finland.",
    "website": "http://www.reveniogroup.fi",
    "zipcode": "01510"
  },
  "TTALO.HE": {
    "city": "Helsinki",
    "country": "Finland",
    "currency": "EUR",
    "exchange": "HEL",
    "industry": "Medical Care Facilities",
    "long_name": "Terveystalo Oyj",
    "market": "fi_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Terveystalo Plc",
    "state": null,
    "summary": "Terveystalo Oyj provides occupational healthcare services in Finland. The company offers general practice and specialist medical care, diagnostic, outpatient surgery, dental, and other adjacent services; and laboratory, imaging, wellbeing, day surgery, healthcare outsourcing, healthcare staffing, and primary and specialty care services. It also provides a suite of digital healthcare services; and clinical research services. The company serves private individuals, companies and communities, insurance companies, and public sector customers. It operates 309 clinics, which include 17 hospital units and 43 dental clinics; and 53 rela massage therapy units. The company was founded in 2001 and is based in Helsinki, Finland.",
    "website": "http://www.terveystalo.com",
    "zipcode": "00100"
  }
}
